<DOC>
	<DOCNO>NCT00488982</DOCNO>
	<brief_summary>This two-arm , randomize Phase II study intermittent chemotherapy without GM-CSF . All patient receive six 21-day cycle docetaxel 75 mg/m2 Day 2 cycle 5 mg prednisone twice day Days 1-21 . Following six cycle chemotherapy , eligible subject randomize maintenance therapy maintenance GM-CSF therapy . The GM-CSF group dose schedule 250 mcg/m2 SQ daily Days 15-28 every 28 day . Patients group continue disease progression time GM-CSF discontinue chemotherapy administer .</brief_summary>
	<brief_title>Intermittent Chemotherapy With Without GM-CSF Metastatic HPRC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Age 18 year 2 . Histologically documented adenocarcinoma prostate 3 . Progressive metastatic prostate cancer 4 . Castrate level testosterone ( &lt; 50 ng/ml ) must maintain 5 . Prior hormonal therapy medication : Patients receive antiandrogen , secondary hormonal therapy ( i.e . ketoconazole , aminoglutethimide , megestrol acetate , diethylstilbestrol ) , 5alpha reductase inhibitor ( i.e . finasteride ( Proscar ) , dutasteride ( Avodart ) ) herbal prostate medication ( i.e . saw palmetto , PCSPES , PCPLUS ) must discontinue drug date initiation chemotherapy study 6 . ≥ 4 week since major surgery fully recover 7 . ≥ 4 week since prior radiation toxicity attributable radiation resolve ≤grade 1 8 . ≥ 8 week since last dose strontium samarium 9 . Sexually active patient must agree use adequate contraception 10 . Karnofsky Performance Status ≥ 60 % 11 . Life expectancy &gt; 12 week 12 . Required initial laboratory value Absolute neutrophil count &gt; 1500/ul Platelets &gt; 100,000/ul Hemoglobin &gt; 8.0 g/dl Creatinine ≤ 2.0 X upper limit normal Bilirubin ≤upper limit normal ( ULN ) AST/ALT/alkaline phosphatase : AST AND ALT AND alkaline phosphatase must within range allow eligibility In determine eligibility , abnormal 2 value ( AST ALT use . An abnormal alkaline phosphatase must attribute liver dysfunction metastatic bone involvement ( i.e elevate GGTP evidence liver metastasis ) Inclusion criterion late enrolling patient : 1 . Age 18 year 2 . Histologically documented adenocarcinoma prostate 3 . ≤3 cycle prior docetaxel chemotherapy metastatic disease permit prior enrollment 4 . Docetaxel must administer every 3 week schedule 5 . Each docetaxel dose must 60 75 mg/m2 6 . Castrate level testosterone &lt; 50 ng/mL 7 . Daily use steroid ( hydrocortisone , dexamethasone ) instead prednisone steroid , permit time enrollment 8 . A PSA level must document within 6 week initiate docetaxel chemotherapy 1 . Prior systemic chemotherapy prostate cancer , q 3week docetaxel/prednisone . Prior neoadjuvant adjuvant chemotherapy permit evidence disease relapse within 12 month last dose chemotherapy . 2 . &gt; 3 cycle q3 week docetaxel/prednisone chemotherapy already administer patient 3 . Peripheral neuropathy &gt; grade 1 4 . Prior immunotherapy include systemic GMCSF vaccine utilize GMCSF ; prior GCSF support chemotherapyrelated neutropenia permit 5 . Prior biologic agent ( i.e. , antiangiogenic agent , antiEGFR inhibitor ) ≤ 4 week prior registration 6 . More two prior therapy investigational agent , complete ≤ 4 week prior enrollment ( prior immunotherapeutics allow ) 7 . Myocardial infarction significant change anginal pattern within last 6 month , symptomatic congestive heart failure ( NYHA Class III high ) uncontrolled cardiac arrhythmia 8 . Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude 9 . Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 exclude 10 . Poorly control diabetes ( fast blood glucose &gt; 250 ) despite optimization medical therapy Exclusion criterion late enrolling patient : 1 . Prior immunotherapy include systemic GMCSF vaccine utilize GMCSF ; prior GCSF support chemotherapyrelated neutropenia permit 2 . Delay ≥6 week 2 chemotherapy cycle prior enrollment study 3 . Cumulative delay ≥8 week chemotherapy cycle prior enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic Hormone Refractory Prostate Cancer</keyword>
</DOC>